Immuneering (IMRX) Operating Income (2020 - 2026)
Immuneering (IMRX) posted quarterly Operating Income of -$15.3 million for Q1 2026, up 0.97% year-over-year from -$15.2 million in Q1 2025, and down 11.51% quarter-over-quarter from -$13.8 million in Q4 2025.
Immuneering (IMRX) Operating Income (2020 - 2026) Analysis & Trends
Immuneering's Operating Income history runs 7 years deep, the most recent figure standing at -$15.3 million for Q1 2026.
- In Q1 2026, Operating Income rose 0.97% year-over-year to -$15.3 million; the TTM figure through Mar 2026 stood at -$59.2 million (up 7.79% YoY), while the FY2025 annual figure was -$59.4 million, up 7.33% from the prior year.
- Operating Income for Q1 2026 stood at -$15.3 million, down from -$13.8 million in the prior quarter.
- The five-year high for Operating Income was -$11.6 million in Q2 2022, with the low at -$18.6 million in Q4 2024.
- The 5-year median for Operating Income is -$14.8 million (2025), against an average of -$14.6 million.
- The sharpest annual moves came in 2022 and 2025: Operating Income plunged 107.27% in 2022, then climbed 25.89% in 2025.
- Immuneering's Operating Income stood at -$14.0 million in 2022, then dropped by 16.57% to -$16.3 million in 2023, then dropped by 13.84% to -$18.6 million in 2024, then grew by 25.89% to -$13.8 million in 2025, then dropped by 11.51% to -$15.3 million in 2026.
- Business Quant data shows IMRX's Operating Income at -$15.3 million in Q1 2026, -$13.8 million in Q4 2025, and -$15.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Immuneering | 327.37 Mn | 327.37 Mn | - | -19.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -19.00 Mn |
| Mar 31, 2026 | -15.34 Mn |
| Dec 31, 2025 | -13.75 Mn |
| Sep 30, 2025 | -15.38 Mn |
| Jun 30, 2025 | -14.76 Mn |
| Mar 31, 2025 | -15.48 Mn |
| Dec 31, 2024 | -18.56 Mn |
| Sep 30, 2024 | -15.27 Mn |
| Jun 30, 2024 | -14.91 Mn |
| Mar 31, 2024 | -15.33 Mn |
| Dec 31, 2023 | -16.30 Mn |
| Sep 30, 2023 | -13.93 Mn |
| Jun 30, 2023 | -13.50 Mn |
| Mar 31, 2023 | -14.68 Mn |
| Dec 31, 2022 | -13.99 Mn |
| Sep 30, 2022 | -13.19 Mn |
| Jun 30, 2022 | -11.65 Mn |
| Mar 31, 2022 | -12.93 Mn |
| Dec 31, 2021 | -11.12 Mn |
| Sep 30, 2021 | -8.54 Mn |